anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: To provide a control releasable solid medication compd. capable of effecting the multiphasic control release of therapeutically active medicines in the gastrointestinal tracts. CONSTITUTION: This control releasable solid oral administration compd. for active medicine absorption in the gastrointestinal tracts contains (A) the medicines of the amt. effective for exhibiting a therapeutic effect, (B) a control release excipient consisting of a hetero-dispersed rubber matrix contg.  B1 : heteropolysaccharide rubber, for example, xanthan gum and B2 : homopolysaccharide rubber capable of crosslinking a B1 component in the presence of an aq. soln., for example, Carob (Ceratonia siliqua L.) rubber at such ratios at which the ratio of B1 and B2 attains 1:3 to 3:1, (C) an inert pharmaceutical diluent which is selected from monosaccharides, disaccharides, polyhydric alcohol and their mixtures and has the ratio to the B components of 3:7 to 7:3, for example, lactose, microcrystalline cellulose, xylitol and (D) a pharmaceutically permissible surfactant or moistening agent of the amt. (usually 1 to 10 wt.%) effective for effecting the multiphasic release of the A components when the compd. described above is exposed to aq. fluid.
The fear response is a crucial adaptive mechanism for coping with environmental changes, and the individuals have different levels of fearfulness. The purpose of this study was to determine the status of the immune response and gut health in hens with different fear responses. A total of 80 healthy 75-wk-old native Lindian chickens were individually housed in conventional cages and categorized into high (TH) and low (TL) levels of fearfulness using the tonic immobility (TI) test. The immunological status and intestinal health of the laying hens were assessed, and the intestinal microbial community was sequenced using 16S rRNA testing. The results showed that the immune-related genes of interleukin (IL)-1β, IL-4, IL-6, and IgG were significantly upregulated in the spleen of TH hens compared with hens in the TL group (P < 0.01). The inflammatory immune-related genes Toll-like receptor (TLR)2, TLR4, nuclear factor (NF)-κB, inducible nitric oxide synthase (iNOS), cyclooxygenase (COX)-2, IL-10, and IgG were significantly increased in the intestinal tract, whereas IL-4, IgA, and the intestinal barrier gene claudin-4 were significantly decreased in TH hens (P < 0.05). In addition, serum concentrations of IL-1β, IL-6, IL-10, interferon (IFN)-α and IgG were significantly higher in TH hens (P < 0.01). A high fear response also led to changes in gut microbial diversity, with a higher Simpson's index and lower β-diversity similarity than hens with a low-fear response (P < 0.05). The TH group showed an increase in 8 genera, including Bacillaceae and Coprococcus, whereas the genus Anaerorhabdus decreased (P < 0.05). The gut microbiota has also been associated with gut barrier genes, and inflammatory cytokines. Bartonella stimulates IL-1β and IgG secretion, whereas Lactobacillus inhibits IL-6 secretion, and Coprococcus and Subdoligranulum are associated with the maintenance of intestinal barrier function. The results of this study suggest that laying hens with high fear response levels have a more sensitive immune response and a more enriched gut microbiota, which may have positive effects on adapting to a complex environment.
BL33 and BL35 of both sides are used. Every session will last for 30 minuets and will be given every other day. There are 36 sessions for each participant in all (3 session per week, 12 weeks).
Study visit: Subjects will receive a caffeine free, standardized evening meal and remain fasting overnight. An IV infusion of glucose (50%) will be given the next morning together with an IV infusion of Clinisol 15% (an amino acid mixture) will be given the next morning and continue until the end of study. Blood draws will be collected frequently from the IV line to monitor blood glucose levels.
In the first stage of the study, patients newly diagnosed with breast cancer will be interviewed using a semi-structured method. Based on the transcriptions from the interviews, themes will be gathered and transformed into questions. The questions will be compiled into a questionnaire and an expert group will review the questionnaire to ensure no topic is lacking and an adequate number of response options is present. Lastly, the questionnaire will be face-to-face validated, meaning a patient completes it with a research nurse present to apprehend any ambiguities or questions needing clarification.

In the second part of the pilot study, patients will be included to test the feasibility of the interventions consisting of expressive writing. The intervention consists of expressive writing during 20 minutes. The writing should be of the breast cancer, the treatment or other related topics. The patient is invited to write once every week in a separate place. The intervention ends after four weeks. The written text is not collected. In the pilot study, the intervention will be followed by a telephone call about five weeks after inclusion. To test the feasibility of the intervention, 20 to 25 included patient is considered sufficient.
NEW MATERIAL:The compound of formula I [X is H, halogen, lower alkyl, lower alkoxy or di(lower alkyl)amino; R<1> is H or lower alkyl; R<2> is lower alkyl, benzyl, thienylmethyl, or benzyl or thienylmethyl substituted with lower alkyl, lower alkoxy or methylenedioxy]. EXAMPLE:2,3-bis(p-Methoxyphenyl)-5-methylpyrazine. USE:Medicinal drug. A platelet coagulation inhibitor. It remarkably suppresses the platelet coagulation action induced by arachidonic acid or collagen, and is used for the prevention of diseases caused by the coagulation of platelet, especially ischemic attach after myocardial infarction and cerebral hemorrhage. It has cyclooxygenase-inhibiting activity and can be used as an anti- inflammatory agent. PREPARATION:The compound of formula I can be produced by heating the benzyl derivative of formula II and the 1,2-diamine derivative of formula III in an organic solvent and heating the resultant compound of formula IV together with sulfur at 100-180 deg.C.
Albuterol Spiromax, 180 mcg (2 inhalations of 90 mcg/inhalation), single dose on Day 1. Placebo Spiromax (2 inhalations), single dose on approximately Day 7.
This is a prospective natural history study examining individuals, both females and males who do not meet criteria for Rett syndrome, but have a mutation in MECP2, CDKL5, or FOXG1. No interventions are planned.
The prevalence of asthma is rising sharply in the UK. The house dust mite is the most common trigger associated with asthma, thriving in the humid microclimate favoured by modern housing. Could this be redressed by investment in improved ventilation in local housing? In a pilot study in North Lanarkshire Council housing stock, we demonstrated that dust mite avoidance, in combination with installation of domestic mechanical heat recovery ventilation (MHRV), could inhibit the re-colonisation of house dust mites by reduction of indoor air humidity. In this second phase, a double blind randomized placebo- controlled trial will test the resultant effect on asthma. It will be complete in November 2006. 140 patients with asthma and house dust mite allergy are being recruited and all will have new bedding, mattress covers and carpets cleaned. All will have MHRV units installed in their home, but only half will be activated, before 12 months of environmental and clinical monitoring. The primary endpoint is morning peak flow rate. Secondary endpoints include symptom scores, spirometry, rates of exacerbations, quality-of-life, and economic evaluations. Demonstration that well ventilated, energy efficient dwellings improve the respiratory health of patients with allergic asthma could be of considerable importance in helping the NHS cope with the commonest chronic disease in Scotland.
The invention provides a polypeptide with tumor blood vessel targeting property, a molecular probe, a preparation method and an application thereof, belonging to the technical field of diagnostic imaging agents. The polypeptide has an amino acid sequence shown in a sequence table Seq ID No. 1. The single photon or positron molecular probe has a structure shown as X-N-G; wherein X is the single photon imaging nuclide or positron imaging nuclide, N is a bifunctional chelating agent, and G is the polypeptide. The fluorescent molecular probe has a structure shown as X-G; wherein X is the fluorescent nuclide and G is the polypeptide. The modified polypeptide can obviously reduce the background of the abdomen, improve the contrast of the image, and the obtained molecular probe has the advantages of simple preparation, low price and higher target/non-target ratio.
PROBLEM TO BE SOLVED: To detect a cancer originating from a non-epithelium by allowing antibodies UCD/PR 10 and 11 or another antibody with a specificity being similar to them to react with the sample of cancer cell, and forming a specific antibody-light source compound. SOLUTION: A cytokeratin outside cell is discharged during circulation by a tumor epithelium cell. It has a molar amount of approximately 40-46 k dalton and is related to a protein with a molar amount of approximately 42-48 k dalton on the cell surface of the cancer-like epithelium cell. Antibodies UCD/PR 10 and 11 easily react with the cell inner and outer shapes of cytokeratin, especially the cytokeration of type 8 that is specifical to a tube epithelium. Also, the antibodies UCD/PR 10 and 11 are useful for screening cancel cells for determining whether they originate from the epithelium or not. Further, they have a high affinity of the epithelium and accompany an extremely low background level and achieve a highly specific dyeing.
TITLE OF THE INVENTION:             RAPID SETTING HIGH BOND STRENGTH ADHESIVE             ABSTRACT OF THE DISCLOSURE:   Disclosed is a rapid setting adhesive of low toxicity having high bond strength to a variety of metals and plastics, and particularly to stainless steel, polycarbonate plastics and tooth enamel.  The composition consists essentially of (A) a resin which is formed from an ester of methacrylic acid with a monoalcohol containing at least one epoxy group and (B) a filler which may be any of a plurality of finely divided materials that are insoluble in ambient fluids or a mixture of such fillers, parts (A) and (B) being present in a weight ratio such that the initial mixture at ambient temperature and pressure is a viscous liquid or paste.  Also included are minor amounts of a conventional polymerization catalyst and a conventional polymerization accelerator.  Preferably parts (A) and (B) are packaged separately, with polymerization catalyst included in only one package.  In one embodiment of the invention, to insure thermostability at elevated temperatures, about 10 to about 80 parts by weight, per 100 parts of (A) plus (B), of an aliphatic or aromatic dimethacrylate is added as a cross-linking agent.  In a preferred embodiment (A) is glycidyl methacrylate.  Many variations are possible within the scope of the invention depending upon the viscosity, set time and mechani-cal bond strength desired for a particular end use.
Pilot data will be collected to evaluate image quality and collect preliminary information on the uptake of \[18F\]F-Gln in breast cancer. Uptake measures will be compared to tumor markers of glutamine metabolism, when tissue is available. The safety of \[18F\]F-Gln will also be evaluated in all subjects.
The invention belongs to the field of organic synthesis, relates to a synthesis method of a halogenated alkoxyl product of an olefin and concretely relates to a synthesis method of a halogenated alkoxyl alcohol ester of an olefin. A halogenation agent, an organic acid, a cyclic ether and an olefin as raw materials undergo a chemical reaction under the action of asymmetric catalysis. According to halogen-mediated nucleophilic conjugate addition and cyclic ether ring-opening reaction principles, high yield addition of inertial an olefins with multiple structures is realized so that the synthetic halogenated alkoxyl ester is obtained. In the structural formula, R1 represents phosphate radical or sulfonate radical. The synthesis method has the characteristics of operation easiness, high efficiency, safety, low cost and production expansion. The product has the activity of resisting chronic granulocytic leukemia, lung adenocarcinoma, pancreas cancer, breast cancer, brain cancer or prostate cancer cells.
The TGlittre-P is an adaptation of the TGlittre test for pediatric patients. It consists of completing a circuit while carrying a backpack with a variable weight of 0.5 kg to 2.5 kg, according to the child´s age and sex. This weight range follows the guidelines of the World Health Organization, which states that the younger the female child is, the lighter the backpack should be, in order to assure the school children´s health condition. The following tasks should be carried out; from a sitting position, the child stands up and walks along a 10m-long flat course, going up and down a 2-step rise (17 cm high x 27 cm wide) about halfway along that distance, to reach a bookshelf with three 0.5 kg objects (i.e. colorful plastic bowling pins filled with sand). The objects are placed on the top shelf at eye level, which should be removed, one by one, to the lower shelf at the level of the umbilicus, and then to the ground. Next, the objects should be placed on the lower shelf and then back to the top shelf. The child walks back along the same route. (S)he sits down, stands up and immediately starts the next lap. The following verbal instructions are given during the test: "sit" and "stand." The time required to walk five laps is registered; the less the time spent, the better the performance is. The test performance was evaluated by comparing the patient´s data with the data predicted by the equation, in his study with healthy children. The equation for girls is "time in TGlittre-P = 3.781-0.083 x AGE"; and boys, "time in TGlittre-P = 4.025-0.123 x AGE".
PURPOSE:To provide a permanent wave lotion capable of activating an oxidizing agent utilizing the alkaline component in the permanent wave lotion, and bleaching black hair to chestnut color hair. CONSTITUTION:After the completion of permanent wave treatment, the oxidizing agent (hydrogen peroxide) is activated utilizing the alkaline component remaining on the hair to effect the bleaching of black hair to chestnut color. The permanent wave lotion is an agent to impart hair with waving effect either by the combination of a reducing agent and an oxidizing agent or by the use of only the reducing agent, and contains usually an alkaline agent to improve the effect of the reducing agent. Accordingly, the alkaline agent is left on the hair after the treatment. On the other hand, the bleaching agent is an agent for bleaching the hair and composed of a mixture of an alkaline agent and an oxidizing agent, and the combined use of the bleaching agent and the permanent wave lotion is impossible because the effects of both agents are lost. However, the above process enables the bleaching of the hair and the permanent wave treatment at the same time in a short time at a low cost.
<P>PROBLEM TO BE SOLVED: To provide a system and a method for uniquely identifying data stream associated with medical equipment.  <P>SOLUTION: This system is implemented in a variety of ways, including as a combination of a medial device, a data stream identifier and a medical device identifier. The medical device generates a plurality of data streams. The data streams are uninterrupted transmissions of data from the medical device. The data streams include information regarding the operation of the medical device. The data stream identifier attaches a unique data tag to the data streams. The medical device identifier is configured to generate a medical device tag. The medical device tag includes information to uniquely identify the medical device and is accessible from an external computer. The data stream identifier and the medical device identifier are secured to the medical device.  <P>COPYRIGHT: (C)2011,JPO&INPIT
The nicotine inhalation group will smoke a cigarette to completion of their choice, in the 20 minute time period allocated in the Exercise and Health Psychology Lab psychological assessment room (the room will be equipped with windows that allow for ventilation and an air purifier. During this time the participant will refrain from conversation.
An EA 25/04 tip was coated with AH Plus and activated in the root canals for 10 seconds. Then, the R40 gutta-percha was coated with the sealer and inserted into the canal, and the root canals were filled using SCT.
PURPOSE: A cosmetic composition containing bamboo sap and herb extract is provided to suppress T type lymphocyte-mediated immune reaction and to treat atopic dermatitis, contact dermatitis, and psoriasis. CONSTITUTION: A cosmetic composition for treating atopic dermatitis contains bamboo sap and herb material extract. The herb material is Asiasari Radix, Perillae Herba, Perillae Semen, Cimicifugae Rhizoma, Melandrii Herba, Solani Nigri Herba, Arctii Semen, Potentillae Radix, Cinnamomi Cortex Spissus, Hoelen rubra, Phaseoli angularis Semen, Ammomi Tsao-ko Frucuts, Alpiniae Katsumadaii Semen, Fagopyrum esculentum, Chenopodium album var. centrorubrum, or Pimpinella brachycarpa. The bamboo sap is contained in 0.01-99.5 weight% based on total composition. The herb extract is contained in 0.001-10 weight% based on total composition.
All procedures will be performed by experienced endoscopists (\>3 years of experience/\>1000 polypectomies) with the patient in the left lateral position under propofol sedation.submucosal injection of saline mixed with methylene blue will be used (no epinephrine) followed by resection using snare without using electrocautery in C-EMR group.The polyp size will be assessed by boston biopsy forceps (open jaws -7mm) or boston jumbo biopsy forceps (open jaws 10mm) or submucosal injection needle (Olympus (4mm)). A standard snare will be used.After polypectomy, the area is inspected for residual polyp using NBI and if present, will be resected using biopsy forceps.
The present invention relates to the pharmaceutically-induced enhancement of DNA damage repair in cells and potential therapeutic applications thereof. In particular, the present invention is directed to an inhibitor of DREAM complex assembly and/or function for use in repairing DNA damage in a cell of a subject. The inhibitor of DREAM complex assembly may be an inhibitory nucleic acid inhibiting the expression of a component of the DREAM complex or an antibody to a component of the DREAM complex. Further disclosed is an inhibitor of DREAM complex assembly and/or function for use in treating and/or preventing a condition associated with DNA damage in a cell in a subject, such as age-related diseases and symptoms of ageing, a progeroid syndrome, acute radiation syndrome, chronic radiation syndrome, Xeroderma pigmentosum, Nijmegen breakage syndrome, Fanconi anemia and ataxia. The invention further discloses a method for obtaining at least one cell with reduced DNA damage, wherein the method comprises steps of providing at least one cell, and treating said at least one cell with an inhibitor of DREAM complex assembly and/or function to repair DNA damage in said cell. Finally, the invention provides pharmaceutical compositions comprising the at least one cell obtainable by said method.
The present invention relates to equine fetal tissue-derived stem cells, and a cell therapeutic agent for regenerating a musculoskeletal system, comprising same, and, more particularly, to: a method for preparing equine amniotic fluid-derived stem cells; the analysis of characteristics of amniotic fluid stem cells prepared by the method; equine amniotic fluid-derived stem cells comprising the stem cells as an active ingredient; and a cell therapeutic agent for regenerating a musculoskeletal system, comprising same. The present invention provides equine amniotic fluid-derived stem cells. In addition, the present invention provides a method for preparing equine amniotic fluid-derived mesenchymal stem cells, comprising the steps of: (step 1) collecting amniotic fluid from a pregnant horse; (step 2) isolating monocytes from the collected amniotic fluid; and (step 3) initially culturing the isolated amniotic fluid-derived monocytes. Moreover, the present invention provides a method for preparing equine mesenchymal stem cells, comprising the steps of: (step 1) collecting amniotic fluid from a pregnant horse; (step 2) isolating monocytes from the collected amniotic fluid; (step 3) initially culturing the isolated amniotic fluid-derived monocytes; (step 4) culturing the initially cultured equine amniotic fluid-derived cells of passages 3 to 5 by using the culture medium Dulbecco's Modified Eagle Medium (DMEM), which contains 10-20% fetal bovine serum (FBS), 0.5-1.5% glutamax, and 0.5-1.5% penicillin/streptomycin; and (step 5) removing the medium in a culture dish, washing same with phosphate buffered saline (PBS, pH 7.2), and then separating cells from the basal surface by using 0.01-0.1% Typsin-EDTA. The present invention also provides equine amniotic fluid-derived stem cells having a musculoskeletal system treatment function. Furthermore, the present invention provides a cell therapeutic agent for regenerating a musculoskeletal system, comprising the equine amniotic fluid-derived stem cells.
Hyperthyroidism is associated with the alteration in molecular pathways involved in the regulation of mitochondrial mass and apoptosis, which contribute to the development of cardiac hypertrophy. Diminazene (DIZE) is an animal anti-infection drug that has shown promising effects on improving cardiovascular disease. The aim of the present study was to investigate the therapeutic effect of DIZE on cardiac hypertrophy and the signaling pathways involved in this process in the hyperthyroid rat model. Twenty male Wistar rats were equally divided into four groups: control, hyperthyroid, DIZE, and hyperthyroid + DIZE. After 28 days of treatment, serum thyroxine (T4) and thyroid stimulating hormone (TSH) level, cardiac hypertrophy indices, cardiac damage markers, cardiac malondialdehyde (MDA), and superoxide dismutase (SOD) level, the mRNA expression level of mitochondrial and apoptotic genes were evaluated. Hyperthyroidism significantly decreased the cardiac expression level of SIRT1/PGC1α and its downstream involved in the regulation of mitochondrial biogenesis, mitophagy, and antioxidant enzyme activities including TFAM, PINK1/MFN2, Drp1, and Nrf2, respectively, as well as stimulated mitochondrial-dependent apoptosis by reducing Bcl-2 expression and increasing Bax expression. Treatment with DIZE significantly reversed the downregulation of SIRT1, PGC1α, PINK1, MFN2, Drp1, and Nrf2 but did not significantly change the TFAM expression. Moreover, DIZE suppressed apoptosis by normalizing the cardiac expression levels of Bax and Bcl-2. DIZE is effective in attenuating hyperthyroidism-induced cardiac hypertrophy by modulating the mitophagy-related pathway, suppressing apoptosis and oxidative stress.